Details of the Drug Combination

General Information of Drug Combination (ID: DCBRZMT)

Drug Combination Name
Arfolitixorin Aminolevulinic Acid Hydrochloride
Indication
Disease Entry Status REF
Melanoma Investigative [1]
Component Drugs Arfolitixorin   DMIXMYK Aminolevulinic Acid Hydrochloride   DMWNHPC
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: SK-MEL-2
Zero Interaction Potency (ZIP) Score: 8.31
Bliss Independence Score: 12.6
Loewe Additivity Score: 6.06
LHighest Single Agent (HSA) Score: 6.31

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Arfolitixorin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]
Indication(s) of Aminolevulinic Acid Hydrochloride
Disease Entry ICD 11 Status REF
Actinic keratosis EK90.0 Approved [3]
Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Protoporphyrinogen oxidase (PPOX) TTNFMS9 PPOX_HUMAN Modulator [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DC4XK0M MOLT-4 Investigative [5]
Anaplastic large cell lymphoma DCD3VLZ SR Investigative [5]
Invasive ductal carcinoma DCN8QZU BT-549 Investigative [6]
Adenocarcinoma DCLPFO0 HT29 Investigative [1]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.